Coastline Trust Co Decreases Stock Position in Eli Lilly and Company $LLY

Coastline Trust Co decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 5.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 19,745 shares of the company’s stock after selling 1,123 shares during the quarter. Eli Lilly and Company accounts for approximately 2.1% of Coastline Trust Co’s investment portfolio, making the stock its 14th largest position. Coastline Trust Co’s holdings in Eli Lilly and Company were worth $22,847,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Integrity Financial Corp WA lifted its stake in Eli Lilly and Company by 1.3% in the 2nd quarter. Integrity Financial Corp WA now owns 639 shares of the company’s stock valued at $767,000 after purchasing an additional 8 shares during the last quarter. Willner & Heller LLC increased its holdings in shares of Eli Lilly and Company by 1.0% during the second quarter. Willner & Heller LLC now owns 917 shares of the company’s stock worth $1,100,000 after buying an additional 9 shares in the last quarter. Aspiring Ventures LLC lifted its stake in shares of Eli Lilly and Company by 3.7% in the 2nd quarter. Aspiring Ventures LLC now owns 255 shares of the company’s stock valued at $306,000 after acquiring an additional 9 shares during the last quarter. Wealthspan Partners LLC lifted its stake in shares of Eli Lilly and Company by 0.4% in the 2nd quarter. Wealthspan Partners LLC now owns 2,120 shares of the company’s stock valued at $2,543,000 after acquiring an additional 9 shares during the last quarter. Finally, Navigoe LLC boosted its holdings in shares of Eli Lilly and Company by 8.7% during the 2nd quarter. Navigoe LLC now owns 113 shares of the company’s stock valued at $135,000 after acquiring an additional 9 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Foundayo delivered encouraging Phase 3 data. Lilly’s oral GLP-1 met its primary endpoint in the ATTAIN-1 study, while post-hoc analyses indicated a potential 57% reduction in predicted 10-year type 2 diabetes risk and an 18% reduction in predicted cardiovascular-disease risk versus placebo. The treatment also demonstrated cardiovascular safety, sustained A1C improvement and weight loss in the ACHIEVE-4 diabetes study. Lilly Foundayo risk-reduction results
• Positive Sentiment: Lilly’s next-generation obesity pipeline strengthened. The experimental EloraTZP combination produced substantially greater weight loss and A1C reduction than Zepbound alone in a Phase 2b trial, supporting plans to begin Phase 3 testing in the fourth quarter. Separate Phase 3 data showed retatrutide produced average weight loss of nearly 21% in adults with diabetes and obesity. EloraTZP trial results
• Positive Sentiment: Additional pipeline data broadened the growth story. Lilly reported positive results for EBGLYSS in hand and foot atopic dermatitis, including improved skin clearance, itching and pain. The company is also presenting obesity and diabetes data at the EASD meeting, reinforcing its competitive position in GLP-1 medicines. EBGLYSS trial results
• Neutral Sentiment: Competition remains intense. Novo Nordisk reported real-world evidence favoring higher-dose Ozempic over Mounjaro on observed cardiovascular risk, while other pharmaceutical companies are advancing competing oral and next-generation obesity treatments. The findings could increase uncertainty around Lilly’s long-term market share, even as its own clinical data remain strong. Novo cardiovascular comparison
• Negative Sentiment: The valuation leaves less room for disappointment. After a multiyear rally, investors are increasingly focused on whether future cash flows justify Lilly’s premium valuation. Concerns about potential U.S. price pressure and the stock’s recent decline may be contributing to profit-taking.
• Negative Sentiment: Lilly ended its cancer partnership with Foghorn Therapeutics. The collaboration was discontinued after disappointing early-stage results, and Foghorn plans significant layoffs. While the financial impact on Lilly appears limited, the decision highlights the risks in its broader development pipeline. Foghorn partnership termination

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This represents a 29.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock worth $15,958,170 over the last ninety days. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Trading Down 0.8%

LLY traded down $9.69 during midday trading on Thursday, hitting $1,147.39. 825,816 shares of the company were exchanged, compared to its average volume of 2,985,028. The firm’s 50 day moving average price is $1,178.06 and its 200-day moving average price is $1,087.21. Eli Lilly and Company has a 1-year low of $783.85 and a 1-year high of $1,292.65. The firm has a market capitalization of $1.08 trillion, a P/E ratio of 38.46, a P/E/G ratio of 1.45 and a beta of 0.50. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The company had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. During the same quarter in the prior year, the firm posted $6.31 earnings per share. The business’s quarterly revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 36.66 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on LLY shares. BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a report on Wednesday, September 9th. Jefferies Financial Group lifted their price target on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research note on Tuesday, June 9th. Wells Fargo & Company upped their price objective on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Leerink Partners raised their price objective on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. Finally, Truist Financial lifted their target price on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,311.96.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.